Publications

Peripheral immune features associated with severe adverse events in melanoma

Healy & Kovacsovics-Bankowski et al. SITC (2022)

Poster Highlights

Immune-related adverse events (irAEs) are major barriers to clinical management and further development of cancer immunotherapy.

We used mass cytometry to characterize the immune system before and during presentation of severe (grade 3+ that required clinical intervention) irAEs to identify cell signatures correlated with irAE development.

We found that patients with severe irAE have fewer immunosuppressive cells at baseline and more activated and tumor-reactive T cells during irAE presentation.

These findings suggest severe irAEs are the result of a lower baseline state of immunosuppression.

Download Poster PDF

Reference citation: Healy C, Kovacsovics M, Sigal N, et al. 44: Immune signatures of severe immune-related adverse events detected by mass cytometry immune profiling in blood in patients with advanced melanoma treated with immunotherapy. Journal for ImmunoTherapy of Cancer. 2022. doi: 10.1136/jitc-2022-SITC2022.0044

White background with black and red text in the middle surrounded by squares of abstract red paint splotches. The title reads "Teiko.bio Peripheral immune Monitoring" and the subtitle reads "What looking beyond the tumor microenvironment taught us about immunotherapy."

What looking beyond the tumor microenvironment has taught us about immunotherapy

Dr. Jolien Sweere walks us through scientific publications showing that immune responses outside the tumor are necessary for effective immunotherapy.

Customer Spotlight: Shernan Holtan, MD

Dr. Shernan Holtan discusses her research into a pregnancy hormone that may hold the key to treating life-threatening graft-vs-host diseases and how Teiko helped her overcome the barriers to high-dimensional immune profiling.

Five things to look for in an immune profiling partner

Make the most of your time and resources by choosing an immune profiling partner who can advance your oncology, autoimmune, or infectious disease pipelines. Here are five things to look for when evaluating an immune profiling partner.

Poster Highlights

Download Poster PDF

You Might Also Like

What looking beyond the tumor microenvironment has taught us about immunotherapy

Customer Spotlight: Shernan Holtan, MD

Five things to look for in an immune profiling partner